This site is intended for US healthcare professionals only.

HCP Education Portal

Congenital Adrenal Hyperplasia (CAH): Study Insights from CAHtalyst™ Adult: 8-Week Rapid Protocolized GC Dose Reduction, Including Long-term, 12-Month Data

Presented by
Gnangurudasam Prakasam,
MD

Medical Director

Sutter Medical Center

Presented on November 18, 2025

Congenital Adrenal Hyperplasia (CAH): Study Insights from CAHtalyst™ Pediatric: Androgen and GC Dose Reduction Including Long-term, 12-Month Data

Presented by
Ian Marshall,
MD

Professor of Pediatrics

Chief, Division of Pediatric Endocrinology

Rutgers-Robert Wood Johnson Medical School

Presented on November 12, 2025

Congenital Adrenal Hyperplasia (CAH): Study Insights from CAHtalyst™ Pediatric: Androgen and GC Dose Reduction

Presented by
Kyriakie Sarafoglou,
MD

Professor, Department of Pediatrics

Divisions of Pediatric Endocrinology and Genetics & Metabolism
Department of Experimental & Clinical Pharmacology

University of Minnesota
Director, Center for Congenital Adrenal Hyperplasia and Noah’s Ark and Weiss Family CAH Research Fund and Endowment
University of Minnesota Masonic Children’s Hospital

Presented on March 12, 2025

Congenital Adrenal Hyperplasia (CAH): Study Insights from CAHtalyst™ Adult With 8-Week Rapid Protocolized GC Dose Reductions

Presented by
Richard J. Auchus,
MD, PhD

Professor of Internal Medicine

MEND Division

University of Michigan Medical School

Presented on January 23, 2025

These physicians have been compensated by Neurocrine.